Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly's Alimta among SMC's September recommendations

This article was originally published in Scrip

Executive Summary

Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.

You may also be interested in...



Botox shows hope in chronic migraine

Cerimon receives positive Phase II data on diclofenac patch

Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.

Retroscreen Virology receives €630,000 to start first clinical study of avian influenza vaccine

The UK CRO Retroscreen Virology is planning to start its first clinical study of a novel, culture-based intranasal vaccine against diverse strains of avian influenza (H5N1), along with other members of a European consortium. Other consortium members include Archimedes Development, the University of Leicester, the National Institute of Biological Standards Control, and Evicom.

Topics

Related Companies

UsernamePublicRestriction

Register

SC007197

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel